Great piece and valuable mission. We are keen to combine IPNFTs and the Molecule Protocol and DAO with pay for success contracts/social impact bonds/bounties where healthcare payers agree to pay directly for successful phase 2/3 clinical trial data rather than the irrational and inefficient reliance on the current pharma model on patents and incentivising the charging of the maximum monopoly price for a single drug. It’s also notable that the best medicines are not necessarily the most patentable. This will us to transition into a true open source model of pharma innovation and allow us to leverage the biotech advances of the last 40 years Eg personalised medicine informed by blood/DNA testing to prescribe a unique cocktail of drugs that work best for you